1. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer
   Edoardo Francini et al, 2018, Clinical Genitourinary Cancer CrossRef
2. Taxane-based Chemotherapy Induced Androgen Receptor Splice Variant 7 in Patients with Castration-Resistant Prostate Cancer: A Tissue-based Analysis
   Myungsun Shim et al, 2019, Scientific Reports CrossRef
3. Have we found an optimal sequence in the treatment of metastatic castrationally-resistant prostate cancer?
   Tomáš Svoboda, 2018, Onkologie CrossRef